A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 48,900 shares of CCCC stock, worth $295,356. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,900
Previous 53,600 8.77%
Holding current value
$295,356
Previous $437,000 48.51%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.05 - $8.1 $158,512 - $317,025
39,139 Added 11.7%
373,657 $1.73 Million
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $1.52 Million - $3.16 Million
287,304 Added 608.51%
334,518 $2.73 Million
Q4 2023

Feb 14, 2024

SELL
$1.18 - $6.03 $409,139 - $2.09 Million
-346,728 Reduced 88.01%
47,214 $266,000
Q3 2023

Nov 14, 2023

SELL
$1.81 - $3.89 $498,727 - $1.07 Million
-275,540 Reduced 41.16%
393,942 $732,000
Q2 2023

Aug 14, 2023

BUY
$2.75 - $3.77 $391,402 - $536,576
142,328 Added 27.0%
669,482 $1.84 Million
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $457,727 - $1.33 Million
147,654 Added 38.91%
527,154 $1.66 Million
Q4 2022

Feb 14, 2023

BUY
$5.42 - $10.24 $1.35 Million - $2.56 Million
249,713 Added 192.4%
379,500 $2.24 Million
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $817,743 - $1.3 Million
101,836 Added 364.34%
129,787 $1.14 Million
Q2 2022

Aug 15, 2022

SELL
$5.06 - $26.46 $406,206 - $2.12 Million
-80,278 Reduced 74.17%
27,951 $211,000
Q1 2022

May 16, 2022

SELL
$19.99 - $33.23 $1.07 Million - $1.79 Million
-53,727 Reduced 33.17%
108,229 $2.63 Million
Q4 2021

Feb 14, 2022

BUY
$29.39 - $46.86 $3.57 Million - $5.7 Million
121,621 Added 301.53%
161,956 $5.21 Million
Q3 2021

Nov 15, 2021

SELL
$35.91 - $50.5 $2.53 Million - $3.56 Million
-70,443 Reduced 63.59%
40,335 $1.8 Million
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $2.75 Million - $3.82 Million
90,527 Added 447.02%
110,778 $4.19 Million
Q1 2021

May 17, 2021

SELL
$31.96 - $46.5 $2.67 Million - $3.89 Million
-83,622 Reduced 80.5%
20,251 $749,000
Q4 2020

Feb 16, 2021

BUY
$22.8 - $37.05 $2.37 Million - $3.85 Million
103,873 New
103,873 $3.44 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $295M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.